The deal would allow Sanofi to focus on its more lucrative, but riskier, innovative drugs and vaccines, and CD&R to take a 50% controlling stake in a business that is home to brands such as ...

The US buyout firm is pairing with the French pharma giant to buy out its consumer unit. Success here requires much more than cutting costs. Chris Hughes is a Bloomberg Opinion columnist covering ...

PARIS, Oct 21 (Reuters) - French drugmaker Sanofi (SASY.PA), opens new tab said on Monday it had entered exclusive talks to sell a 50% controlling stake in its consumer health business Opella to U ...

The French pharmaceutical group’s board is scheduled to meet to discuss the planned transaction and finalize measures with CD&R to protect jobs and local plants, the people said, asking not to ...

Most optical drives today are combo CD/DVD drives that support DVDs and all the CD formats: CD audio, CD-ROM, CD-R and CD-RW. The speeds of the drives are rated by their CD-ROM and DVD transfer rates.

Presidio, No. 23 on the CRN Solution Provider 500, is being acquired by private equity behemoth Clayton Dubilier and Rice (CD&R) as part of a bid to expand the $6-billion solution provider’s ...

In September, Bloomberg reported that Sanofi had received two separate bids from CD&R and rival PAI Partners for the Opella unit. CD&R has kept away interest from rival PAI Partners for the unit ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholder With 11,000 talented and passionate people bringing ...

Negotiations between Sanofi and CD&R will now continue, the people said. A deal could be reached within days but is not yet finalised. CD&R’s offer values the business, which makes over-the ...

The renewed negotiations come after CD&R agreed to pledges around local jobs, investments and production, Bloomberg reported earlier. Sanofi encountered a backlash in France when it chose the US firm ...